TScan Therapeutics (NASDAQ:TCRX) Downgraded to “Sell” Rating by Wall Street Zen

Wall Street Zen downgraded shares of TScan Therapeutics (NASDAQ:TCRX) from a hold rating to a sell rating in a research report released on Saturday morning.

Several other brokerages have also commented on TCRX. Barclays dropped their price objective on TScan Therapeutics from $14.00 to $3.00 and set an “overweight” rating on the stock in a report on Friday, March 7th. Needham & Company LLC reissued a “buy” rating and issued a $9.00 price objective on shares of TScan Therapeutics in a report on Tuesday, April 8th. Wedbush reissued an “outperform” rating and issued a $7.00 price objective on shares of TScan Therapeutics in a report on Tuesday, May 6th. HC Wainwright dropped their price objective on TScan Therapeutics from $15.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, May 7th. Finally, Morgan Stanley reissued an “overweight” rating and issued a $10.00 price objective on shares of TScan Therapeutics in a report on Friday, March 14th. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, TScan Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $7.80.

TScan Therapeutics Stock Down 1.3%

Shares of TCRX stock opened at $1.53 on Friday. The firm has a market capitalization of $86.58 million, a PE ratio of -1.44 and a beta of 0.98. TScan Therapeutics has a fifty-two week low of $1.02 and a fifty-two week high of $8.51. The stock’s 50-day simple moving average is $1.46 and its 200-day simple moving average is $2.07. The company has a debt-to-equity ratio of 0.13, a quick ratio of 9.56 and a current ratio of 9.56.

TScan Therapeutics (NASDAQ:TCRX) last posted its earnings results on Monday, May 12th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.02. The firm had revenue of $2.17 million for the quarter, compared to analyst estimates of $1.62 million. TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%. Equities analysts expect that TScan Therapeutics will post -1.12 earnings per share for the current year.

Insider Activity

In other news, major shareholder Lynx1 Capital Management Lp bought 1,200,000 shares of the firm’s stock in a transaction dated Tuesday, May 20th. The shares were acquired at an average price of $1.20 per share, for a total transaction of $1,440,000.00. Following the completion of the transaction, the insider now directly owns 7,946,141 shares in the company, valued at $9,535,369.20. The trade was a 17.79% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 4.35% of the company’s stock.

Hedge Funds Weigh In On TScan Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Prudential Financial Inc. purchased a new position in TScan Therapeutics during the fourth quarter worth approximately $32,000. ProShare Advisors LLC purchased a new stake in TScan Therapeutics in the fourth quarter valued at $40,000. Hsbc Holdings PLC purchased a new stake in shares of TScan Therapeutics in the 1st quarter valued at $49,000. Wells Fargo & Company MN raised its holdings in shares of TScan Therapeutics by 41.1% in the 4th quarter. Wells Fargo & Company MN now owns 19,540 shares of the company’s stock valued at $59,000 after buying an additional 5,694 shares during the period. Finally, Squarepoint Ops LLC purchased a new stake in shares of TScan Therapeutics in the 4th quarter valued at $59,000. Hedge funds and other institutional investors own 82.83% of the company’s stock.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.